TSHR and metastatic neoplasm: Furthermore, the robust expression of the TSHR, being ubiquitous to the thyrocyte, still serves as an important and persistent regulator and physiological marker in primary and metastatic disease with the ability to target the BioNanofluid conjugates for a therapeutic potential.